Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

  1. Geisler, Benjamin ORCID logo
  2. Zahabi, Lara
  3. Lang, Adam Edward
  4. Eastwood, Naomi
  5. Tennant, Elaine
  6. Lukic, Ljiljana
  7. Sharon, Elad
  8. Chuang, Hai-Hua
  9. Kang, Chang-Berm
  10. Clayton-Johnson, Knakita
  11. Aljaberi, Ahmed
  12. Yu, Haining
  13. Bui, Chinh
  14. Le Mau, Tuan
  15. Li, Wen-Cheng
  16. Teodorescu, Debbie
  17. Hinske, Ludwig Christian
  18. Sun, Dennis L.
  19. Manian, Farrin A.
  20. Dunn, Adam G.

Download
s13643-021-01693-7.pdf 500,34KB
WeightNameValue
1000 Titel
  • Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review
1000 Autor/in
  1. Geisler, Benjamin |
  2. Zahabi, Lara |
  3. Lang, Adam Edward |
  4. Eastwood, Naomi |
  5. Tennant, Elaine |
  6. Lukic, Ljiljana |
  7. Sharon, Elad |
  8. Chuang, Hai-Hua |
  9. Kang, Chang-Berm |
  10. Clayton-Johnson, Knakita |
  11. Aljaberi, Ahmed |
  12. Yu, Haining |
  13. Bui, Chinh |
  14. Le Mau, Tuan |
  15. Li, Wen-Cheng |
  16. Teodorescu, Debbie |
  17. Hinske, Ludwig Christian |
  18. Sun, Dennis L. |
  19. Manian, Farrin A. |
  20. Dunn, Adam G. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-05-07
1000 Erschienen in
1000 Quellenangabe
  • 10(1):143
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13643-021-01693-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103882/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Coronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19.!##!Methods!#!This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence.!##!Discussion!#!The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review.!##!Trial registration!#!PROSPERO 2020 CRD42020175648.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Systematic Reviews as Topic [MeSH]
lokal SARS-CoV2
lokal Humans [MeSH]
lokal Repurposing
lokal Repurposed
lokal Middle East respiratory syndrome Coronavirus
lokal COVID-19
lokal Protocol
lokal Severe acute respiratory syndrome
lokal Drug Repositioning [MeSH]
lokal COVID-19 [MeSH]
lokal MERS-CoV
lokal SARS
lokal SARS-CoV-2 [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1704-6067|https://frl.publisso.de/adhoc/uri/WmFoYWJpLCBMYXJh|https://frl.publisso.de/adhoc/uri/TGFuZywgQWRhbSBFZHdhcmQ=|https://frl.publisso.de/adhoc/uri/RWFzdHdvb2QsIE5hb21p|https://frl.publisso.de/adhoc/uri/VGVubmFudCwgRWxhaW5l|https://frl.publisso.de/adhoc/uri/THVraWMsIExqaWxqYW5h|https://frl.publisso.de/adhoc/uri/U2hhcm9uLCBFbGFk|https://frl.publisso.de/adhoc/uri/Q2h1YW5nLCBIYWktSHVh|https://frl.publisso.de/adhoc/uri/S2FuZywgQ2hhbmctQmVybQ==|https://frl.publisso.de/adhoc/uri/Q2xheXRvbi1Kb2huc29uLCBLbmFraXRh|https://frl.publisso.de/adhoc/uri/QWxqYWJlcmksIEFobWVk|https://frl.publisso.de/adhoc/uri/WXUsIEhhaW5pbmc=|https://frl.publisso.de/adhoc/uri/QnVpLCBDaGluaA==|https://frl.publisso.de/adhoc/uri/TGUgTWF1LCBUdWFu|https://frl.publisso.de/adhoc/uri/TGksIFdlbi1DaGVuZw==|https://frl.publisso.de/adhoc/uri/VGVvZG9yZXNjdSwgRGViYmll|https://frl.publisso.de/adhoc/uri/SGluc2tlLCBMdWR3aWcgQ2hyaXN0aWFu|https://frl.publisso.de/adhoc/uri/U3VuLCBEZW5uaXMgTC4=|https://frl.publisso.de/adhoc/uri/TWFuaWFuLCBGYXJyaW4gQS4=|https://frl.publisso.de/adhoc/uri/RHVubiwgQWRhbSBHLg==
1000 Hinweis
  • DeepGreen-ID: 321f76cb8dfa411589082ac86c0a5db8 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6464319.rdf
1000 Erstellt am 2023-11-16T02:36:34.935+0100
1000 Erstellt von 322
1000 beschreibt frl:6464319
1000 Zuletzt bearbeitet Thu Nov 30 23:39:08 CET 2023
1000 Objekt bearb. Thu Nov 30 23:39:08 CET 2023
1000 Vgl. frl:6464319
1000 Oai Id
  1. oai:frl.publisso.de:frl:6464319 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source